6,341 Shares in Evolent Health, Inc. (NYSE:EVH) Acquired by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. purchased a new position in shares of Evolent Health, Inc. (NYSE:EVHFree Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 6,341 shares of the technology company’s stock, valued at approximately $209,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EVH. RA Capital Management L.P. purchased a new position in shares of Evolent Health during the third quarter worth about $74,520,000. Wellington Management Group LLP lifted its holdings in shares of Evolent Health by 11.9% during the third quarter. Wellington Management Group LLP now owns 4,239,198 shares of the technology company’s stock worth $115,433,000 after purchasing an additional 449,664 shares during the period. Vanguard Group Inc. grew its position in Evolent Health by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 10,594,640 shares of the technology company’s stock valued at $288,492,000 after buying an additional 274,288 shares during the last quarter. Redmile Group LLC increased its stake in Evolent Health by 118.0% in the 3rd quarter. Redmile Group LLC now owns 465,282 shares of the technology company’s stock valued at $12,670,000 after buying an additional 251,850 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Evolent Health by 14.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 858,996 shares of the technology company’s stock worth $23,390,000 after buying an additional 107,963 shares during the last quarter.

Wall Street Analyst Weigh In

EVH has been the subject of several analyst reports. JMP Securities cut their price target on shares of Evolent Health from $38.00 to $34.00 and set a “market outperform” rating for the company in a report on Friday, May 10th. Canaccord Genuity Group dropped their price objective on Evolent Health from $44.00 to $41.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Citigroup started coverage on Evolent Health in a research report on Monday, April 22nd. They issued a “buy” rating and a $40.00 price objective for the company. Oppenheimer started coverage on shares of Evolent Health in a research report on Friday, March 1st. They set an “outperform” rating and a $45.00 target price on the stock. Finally, JPMorgan Chase & Co. cut their price target on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Friday, March 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Evolent Health presently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Read Our Latest Analysis on EVH

Evolent Health Stock Down 1.3 %

EVH stock opened at $23.55 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.02 and a quick ratio of 1.01. Evolent Health, Inc. has a 12 month low of $23.33 and a 12 month high of $35.00. The firm has a market capitalization of $2.72 billion, a PE ratio of -18.84 and a beta of 1.57. The company’s 50 day simple moving average is $30.06 and its 200-day simple moving average is $30.24.

Evolent Health (NYSE:EVHGet Free Report) last released its quarterly earnings results on Thursday, February 22nd. The technology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.13. Evolent Health had a positive return on equity of 6.90% and a negative net margin of 5.07%. The company had revenue of $556.06 million during the quarter, compared to the consensus estimate of $541.87 million. Equities analysts expect that Evolent Health, Inc. will post 0.87 earnings per share for the current fiscal year.

Evolent Health Profile

(Free Report)

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

Featured Articles

Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health, Inc. (NYSE:EVHFree Report).

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.